Viral Vectors and Plasmid DNA Manufacturing Market to Reach $34.0 billion by 2033 at 20.4% CAGR: Allied Market Research

Increase in funding for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of global viral vectors and plasmid DNA manufacturing market

PORTLAND, Ore., Feb. 23, 2026 /PRNewswire/ — Allied Market Research published a report, titled, “Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral Vectors, and Non-Viral Vectors) and Application (Cancers, Inherited Disorders, Viral Infections and Others): Global Opportunity Analysis and Industry Forecast, 2024 – 2033.” According to the report, the global viral vectors and plasmid DNA manufacturing market size was valued at $5.3 billion in 2023, and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Request Sample of the Report on Viral Vectors and Plasmid DNA Manufacturing Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/A324540 

Drivers, restraints, and opportunities

Increase in funding for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of the global viral vectors and plasmid DNA manufacturing market. However, high cost of gene therapies and risk of mutagenesis and other impediments impede the growth to certain extent. Nevertheless, upsurge in demand for synthetic genes and untapped markets in developing economies are anticipated to create lucrative opportunities in the industry.

The viral vectors segment to lead the trail by 2033-

Based on product, the viral vectors segment contributed to more than two-thirds of the global viral vectors and plasmid DNA manufacturing market revenue in 2023 and is expected to retain its dominance throughout the forecast period, owing to rise in prevalence of cancer. Simultaneously, the plasmid DNA segment is projected to grow throughout the forecast period. This is due to increase in various applications such as DNA vaccines and gene therapies against numerous infectious and acquired diseases & disorders, such as HIV, malaria, cancer, influenza, and enteric pathogens.

The cancer segment to maintain the lead-

Based on application, the cancer segment accounted for more than three-fifths of the global viral vectors and plasmid DNA manufacturing market revenue in 2033 and is expected to remain dominant till 2033, due to increase in prevalence of cancer and requirement for quality drugs and versatile therapies for the treatment. The inherited disorders segment is anticipated to exhibit the fastest CAGR of 27.1% from 2024 to 2033. Rise in incidences of inherited disorders has led to increase in R&D activities for development of therapies which, in turn, fuels the segment growth.

Which Segment Is Expected to Grow at the Fastest Rate?

The plasmid DNA segment is expected to grow at the fastest rate over the coming years. Plasmid DNA is an important raw material for both viral vector production and non-viral gene delivery approaches. It is also increasingly used in DNA vaccines, mRNA production workflows, and emerging gene-editing technologies. This surge in scope of applications is driving faster demand compared to traditional viral vector systems. There is growing interest in non-viral delivery systems that rely majorly on plasmid DNA. These technologies are appealing due to lower immunogenicity and simpler production requirements. This fuels investment and R&D activity in plasmid-centric platforms. This trend indirectly supports higher growth rates for plasmid DNA manufacturing. 

Further, new applications rely on plasmids for template generation or direct administration. Thus, the demand for high-quality plasmid DNA is experiencing growth, thus, contributing to its faster growth trajectory.

Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A324540 

North America to dominate in terms of revenue-

Based on region, North America generated the major share in 2023, holding nearly half of the global viral vectors and plasmid DNA manufacturing market, owing to the presence of modern healthcare facilities and high prevalence of cancer in the region. Asia-Pacific would showcase the highest CAGR during the forecast period. This is due to increase in healthcare expenditure, surge in government initiatives to modernize healthcare infrastructure, and rapid industrialization in the area.

Role of AI in Viral Vectors and Plasmid DNA

Artificial intelligence plays an important role in viral vectors and plasmid DNA manufacturing. It helps improve speed, accuracy, and scalability. One major impact of AI is in process optimization. Viral vector production involves complex biological systems where small changes in temperature, pH, or nutrient levels can affect yield. AI models analyze datasets from bioreactors and identify patterns that humans may not easily detect. These insights help manufacturers fine-tune conditions to improve viral yield and plasmid quality. 

It also helps predict how genetic sequences will behave inside cells. This allows researchers to design more stable plasmids and efficient viral constructs before laboratory testing begins. Further, AI systems help monitor manufacturing data in real time and flag potential deviations before they become critical problems. This predictive capability reduces batch failures and improves compliance with good manufacturing practices.

Key players in the industry-

• Catalent Pharma Solutions
• Fujifilm Holdings Corporation
• F. Hoffmann-LA Roche Ltd.
• Johnson & Johnson
• Sanofi Corporation
• 4D Molecular Therapeutics
• Sirion Biotech GmbH
• Voyager therapeutics
• Thermo Fisher Scientific, Inc.
• Cognate BioServices, Inc.

For Purchase Related Queries/Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/A324540 

How Can Businesses Strengthen Market Position and Expand Globally?

Companies can strengthen market position by establishing additional good manufacturing practices compliant facilities in strategic regions. Increase in capacity in Asia-Pacific and Europe helps capture new customers. Mergers and acquisitions enable companies to broaden their technology portfolios and enter adjacent markets quickly. Long-term strategic partnerships with biotechnology developers, academic research centers, and pharmaceutical firms provide steady demand and collaborative innovation opportunities. Partnerships can include co-development agreements, platform licensing, or shared manufacturing ventures. These collaborations help align product offerings with emerging therapeutic needs.

Continuous innovation in process optimization, analytics, and automation helps improve productivity and lower costs. Investments in platform technologies help enhance operational flexibility and future-proof manufacturing capabilities.

What Technological Innovations Are Creating New Growth Opportunities?

One major technological innovation in viral vectors and plasmid DNA manufacturing includes development of stable producer cell lines. Viral vectors are produced using transient transfection methods, which can be costly and variable. Stable cell lines provide consistent gene expression and higher yields, reducing cost per dose and improving scalability. Single-use bioreactor systems are also transforming the industry. These disposable systems reduce cleaning requirements, lower contamination risk, and shorten turnaround times between batches. They are especially useful for contract manufacturing organizations serving multiple clients. Continuous manufacturing is another promising advancement. Instead of producing in batches, continuous systems allow ongoing production with steady input and output. This approach increases efficiency and reduces waste.

Explore AMR’s Extensive Ongoing Coverage on Life Science Industry:   

Skincare Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 

Medical Cannabis Market: Global Opportunity Analysis and Industry Forecast, 2023-2032  

Healthcare Staffing Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 

Digital Pathology Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 

Health and Wellness Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:   

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

About Allied Market Research:   

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.    

Contact   
David Correa   
1209 Orange Street,  
Corporation Trust Center,  
Wilmington, New Castle,  
Delaware 19801 USA.  
Toll Free: +1-800-792-5285   
Int’l: +1-503-894-6022   
UK: +44-845-528-1300  
Hong Kong: +852-301-84916  
India (Pune): +91-20-66346060  
Fax: +1-855-550-5975  
help@alliedmarketresearch.com         
Web: https://www.alliedmarketresearch.com            

Logo – https://mma.prnewswire.com/media/636519/5818487/Allied_Market_Research_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/viral-vectors-and-plasmid-dna-manufacturing-market-to-reach-34-0-billion-by-2033-at-20-4-cagr-allied-market-research-302694593.html

SOURCE Allied Market Research